在第2期IMPACT试验中评估免疫检查点阻塞在转移性割抵抗性前列腺癌与有害的CDK12变异中的免疫检查点阻塞
Charles B Nguyen1, Melissa A Reimers2, Chamila Perera3
1Rogel Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan.
概括
免疫检查点抑制剂治疗在 CDK12 改变的转移性割抵抗性前列腺癌 (mCRPC) 患者中显示出最小的活性. 这一第二阶段试验在该患者群体中发现ipilimumab和nivolumab的有效性有限.
科学领域:
- 在瘤学瘤学.
- 癌症遗传学 癌症遗传学
- 免疫治疗是一种免疫疗法.
背景情况:
- 在转移性割抵抗性前列腺癌 (mCRPC) 中观察到CDK12无活化.
- CDK12的改变可能会影响对免疫治疗的反应.
- 评估CDK12改变的mCRPC中的免疫疗法至关重要.
研究的目的:
- 评估免疫检查点抑制剂 (ICI) 治疗在患有mCRPC和CDK12变化的患者中的疗效.
- 为了确定这个特定的患者群体的应答率和生存结果.
主要方法:
- 第二阶段临床试验,招募具有mCRPC和有害CDK12变化的患者.
- 队列A接受了伊皮利穆马布加尼沃卢马布;队列C接受了尼沃卢马布单一治疗.
- 主要终点是前列腺特异性抗原减少50% (PSA50);次要终点包括生存率和反应率.
主要成果:
- 在A组 (ipilimumab + nivolumab) 中观察到9%的PSA50率,其中有两个反应者.
- 在C组 (尼沃卢马布单一治疗) 中没有发现PSA50反应.
- 无PSA进展的中位生存时间为7.0个月 (A组) 和4.5个月 (C组).
结论:
- 免疫检查点抑制剂治疗在CDK12改变的mCRPC患者中显示出最小的活性.
- 可能需要进一步的研究来确定预测生物标志物或替代治疗策略.
相关概念视频
02:34Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K